A decade of rituximab: Improving survival outcomes in non-Hodgkin's lymphoma

Annual Review of Medicine

Volumn 59, Issue , 2008, Pages 237-250

  Molina, Arturo ^a  

^a Ortho Biotech Oncology Research and Development   (United States)

Author keywords

CD20 antigen; Diffuse large B cell lymphoma; Follicular lymphoma; Immunotherapy; Monoclonal antibody

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; BLEOMYCIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB; VINCRISTINE;

B CELL LYMPHOMA; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, NON-HODGKIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 39749182212     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.59.060906.220345     Document Type: Review

References (48)

1. American Cancer Society. 2007. Cancer Facts & Figures 2007. Atlanta, GA: Am. Cancer Soc.
2. The Non-Hodgkin's Lymphoma Classification Project. 1997. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphomas. Blood 89:3909-18
3. Ries LAG, Harkins D, Krapcho M, et al. 2006. SEER Cancer Statistics Review, 1975-2003. Based on Nov. 2005 SEER data submission. Bethesda, MD: Nat. Cancer Inst., http://seer.cancer.gov/csr/1975_2003/
4. Anderson KC, Bates MP, Slaughenhoupt BL, et al. 1984. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63:1424-33
5. Reff ME, Carner K, Chambers KS, et al. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-45
6. Flieger D, Renoth S, Beier I, et al. 2000. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 204:55-63
7. Demidem A, Lam T, Alas S, et al. 1997. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. 12:177-85
8. Maloney DG, Grillo-López AJ, White CA, et al. 1997. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-95
9. Cvetkovic RS, Perry CM. 2006. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 66:791-820
10. Marcus R, Imrie K, Belch A, et al. 2005. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-23
11. Marcus RE, Solal-Celigny P, Imrie K, et al. 2006. MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin's lymphoma. Blood ASH Annu. Meet. Abstr. 108:481
12. Hiddemann W, Kneba M, Dreyling M, et al. 2005. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-32
13. Herold M, Dolken G, Fiedler F, et al. 2003. Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. Ann. Hematol. 82:77-79
14. Herold M, Haas A, Srock S, et al. 2007. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology study. J. Clin. Oncol. 251986-92
15. Salles GA, Foussard C, Mounier N, et al. 2004. Rituximab added to αIFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood ASH Annu. Meet. Abstr. 104:160 (Abstr.)
16. Foussard C, Mounier N, Van Hoof A, et al. 2006. Update of the FL2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma (FL) patients (pts). J. Clin. Oncol. ASCO Annu. Meet. Proc. 24:7508 (Abstr.)
17. Ghielmini M, Schmitz SF, Cogliatti SB, et al. 2004. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416-23
18. Hainsworth JD, Litchy S, Shaffer DW, et al. 2005. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 23:1088-95
19. Hochster HS, Weller E, Gascoyne RD, et al. 2005. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood ASH Annu. Meet. Abstr. 106:349 (Abstr.)
20. van Oers MH, Klasa R, Marcus RE, et al. 2006. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-301
21. Forstpointner R, Unterhalt M, Dreyling M, et al. 2006. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108:4003-8
22. Coiffier B, LePage E, Briere J, et al. 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:235-42
23. Feugier P, Van Hoof A, Sebban C, et al. 2005. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. J. Clin. Oncol. 23:4117-26
24. Habermann TM, Weller EA, Morrison VA, et al. 2006. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin. Oncol. 24:3121-27
25. Pfreundschuh M, Trumper L, Osterborg A, et al. 2006. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 7:379-91
26. McLaughlin P, Grillo-López AJ, Link BK, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16:2825-33
27. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. 1999. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin. Oncol. 26(5 Suppl. 14):79-87
28. Foran JM, Gupta RK, Cunningham D, et al. 2000. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br. J. Haematol. 109:81-88
29. Feuring-Buske M, Kneba M, Unterhalt M, et al. 2000. IDEC-C2B8 (rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann. Hematol. 79:493-500
30. Davis TA, White CA, Grillo-López AJ, et al. 1999. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J. Clin. Oncol. 17:1851-57
31. Piro LD, White CA, Grillo-López AJ, et al. 1999. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10:655-61
32. Colombat P, Salles G, Brousse N, et al. 2001. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97:101-6
33. Solal-Celigny P, Salles GA, Brousse N, et al. 2004. Single 4-dose rituximab treatment for low-tumor burden follicular lymphoma: survival analyses with a follow-up of at least 5 years. Blood ASH Annu. Meet. Abstr. 104:585 (Abstr.)
34. Witzig TE, Vukov AM, Habermann TM, et al. 2005. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J. Clin. Oncol. 23:1103-8
35. Rivas-Vera S, Baez E, Sobrevilla-Calvo P, et al. 2005. Is first line single agent rituximab the best treatment for indolent non-Hodgkin's lymphoma? Update of a multicentric study comparing rituximab vs CNOP vs rituximab plus CNOP. Blood ASH Annu. Meet. Abstr. 106:2431 (Abstr.)
36. Schulz H, Skoetz N, Bohlius J, et al. 2005. Does combined immunochemotherapy with the monoclonal antibody rituximab improve overall survival in the treatment of patients with indolent non-Hodgkin lymphoma? Preliminary results of a comprehensive meta-analysis. Blood ASH Annu. Meet. Abstr. 106:351 (Abstr.)
37. Forstpointner R, Dreyling M, Repp R, et al. 2004. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-71
38. Lenz G, Dreyling M, Hoster E, et al. 2005. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J. Clin. Oncol. 23:1984-92
39. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. 1993. A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 329:987-94
40. National Comprehensive Cancer Network, Inc. 2007. NCCN clinical practice guidelines in oncology - Version 1.2007. Non-Hodgkin's lymphomas. http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf
41. Fisher RI, LeBlanc M, Press OW, et al. 2005. New treatment options have changed the survival of patients with follicular lymphoma. J. Clin. Oncol. 23:8447-52
42. Sacchi S, Pozzi S, Marcheselli L, et al. 2007. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 109:2077-82
43. Sehn LH, Donaldson J, Chhanabhai M, et al. 2005. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J. Clin. Oncol. 23:5027-33
44. Sehn LH, Berry B, Chhanabhai M, et al. 2007. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-61
45. Byrd JC, Rai K, Peterson BL, et al. 2005. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53
46. Keating MJ, O'Brien S, Albitar M, et al. 2005. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23:4079-88
47. Wierda W, O'Brien S, Wen S, et al. 2005. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. 23:4070-78
48. Wierda W, O'Brien S, Faderl S, et al. 2006. A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106:337-45